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Obesity is a world-wide pandemic and its incidence is on the rise along with associated comorbidities. Currently, there are few
effective therapies to combat obesity. The use of lifestyle modification therapy, namely, improvements in diet and exercise, is
preferable over bariatric surgery or pharmacotherapy due to surgical risks and issues with drug efficacy and safety. Although they
are initially successful in producing weight loss, such lifestyle intervention strategies are generally unsuccessful in achieving long-
term weight maintenance, with the vast majority of obese patients regaining their lost weight during followup. Recently, various
compensatory mechanisms have been elucidated by which the body may oppose new weight loss, and this compensation may
result in weight regain back to the obese baseline. The present review summarizes the available evidence on these compensatory
mechanisms, with a focus on weight loss-induced changes in energy expenditure, neuroendocrine pathways, nutrient metabolism,
and gut physiology.These findings have added amajor focus to the field of antiobesity research. In addition to investigating pathways
that induce weight loss, the present work also focuses on pathways that may instead prevent weight regain. Such strategies will be
necessary for improving long-term weight loss maintenance and outcomes for patients who struggle with obesity.
1. Introduction
Obesity is a global public health crisis. Its incidence continues
to rise, and the prevalence of overweight has outstripped that
of underfed [1]. The prevalence of overweight and obesity
has increased over the past three decades [2]. Wang et al.
predict that if rates continue in this fashion, by the year 2030,
86.3% of adults will be overweight or obese and 51.1% will
be obese [2]. According to the 2009-2010 National Health
and Nutrition Examination Survey (NHANES), 78 million
(35.7%) US adults and 12.5 million (16.9%) US children
and adolescents were obese [3]. In addition to being a
widespread health problem on its own, obesity is a risk factor
for the development of chronic diseases such as coronary
heart disease, type 2 diabetes, hypertension, dyslipidemias,
stroke, and cancer [4–6]. In fact, the deleterious effects
of obesity are greater than both smoking and drinking in
terms of overall health conditions and health-related costs
[7]. In 2008, costs to treat obesity totaled $147 billion in
the US [8].
The etiologyvspace of obesity is believed to be multifac-
torial, with both genetic and environmental contributions. A
key determinant of obesity is the balance between ingested
calories and the body’s basal energy expenditure. Obesity
therefore results when small positive energy balances accu-
mulate over a long period of time [9, 10]. Presently, of the one-
third of Americans who are obese, an estimated 50%–70%
are trying to lose weight [11–13]. Lifestylemodification, which
generally consists of a combination of nutrition, physical
activity, and behavioral modification is an oft-used strategy
to help patients achieve weight loss and maintenance [14, 15].
In their study to identify strategies associated with losing 5%
and 10% of body weight among obese US adults, Nicklas et
al. reported that the most popular strategies among obese
participants trying to lose weight were eating less, exercising
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more, eating less fat, and switching to lower-calorie foods
[16]. However, conventional weight loss strategies such as
diet and exercise as well as medical therapy have not shown
effectiveness in treating severe obesity in the long term [17].
The only known effective treatment for severe obesity is
bariatric surgery, also known as weight loss surgery. Bariatric
surgery has been shown to dramatically improve or resolve
comorbidities associated with obesity, such as type 2 diabetes,
hypertension, sleep apnea, and dyslipidemia [18].
Despite the efficacy of bariatric surgery, lifestyle modi-
fication therapies may be preferable to surgery since many
patients are poor candidates for the operation and some may
suffer postsurgical complications [19].This difficulty, coupled
with the limited efficacy of targeted obesity therapeutics,
makes lifestyle modification a potentially favorable inter-
vention [17]. However, a major barrier exists to its efficacy:
weight regain.This regain is a commonoccurrence in patients
who have lost weight by implementing lifestylemodifications,
regardless of the dietary or behavioral intervention used.
Approximately 30%–35% of lost weight is regained one year
following treatment and 50% of patients will return to their
baseline weight by the fifth year out from weight loss [20].
According toNHANES (1999–2006), amere 1 in 6 overweight
and obese adults reported maintaining weight loss of at least
10% for 1 year, at any point in their lives [21].
Body weight, feeding, and energy metabolism are reg-
ulated by a variety of hormones derived from the gut,
adipose, and other tissues.These distinct signals are centrally
integrated by the hypothalamus, which responds through
key neuroendocrine axes that regulate energy expenditure,
activity level, and feeding [22]. It has been speculated that the
body cannot distinguish between dieting and starvation and,
as such, the body’s first response to weight loss is to prevent
adverse effects of starvation [22]. The body exerts profound
changes on the neuroendocrine milieu, promoting weight
regain [22]. The present review discusses recent research
highlighting these weight loss-induced alterations promoting
weight regain in obese patients.
2. Energy Expenditure and
Nutrient Metabolism
Energy expenditure varies according to changes in body
weight. Consequently, weight fluctuation may be a key
player in weight maintenance once weight is lost. Resting
energy expenditure (REE) is defined as the energy needed
to fuel minimal daily functions of cells and organs [23, 24].
Total energy expenditure (TEE) represents a compilation of
expenditures, including resting metabolic rate, diet-induced
thermogenesis, and activity-related energy expenditure [25].
Higher body weights are associated with a much higher TEE
and a higher total energy intake [9]. Weight loss leads to
a decrease in REE [26], which accounts for approximately
60 percent of TEE in humans [27]. Following weight loss,
a decrease in REE is thought to lead to weight gain [28],
suggesting a vicious cycle of obesity, followed by weight
loss, followed by weight regain, followed by obesity, and
so on. The concept of weight loss leading to a decrease in
energy expenditure is known as “adaptive thermogenesis”
and evidence suggests that these changes increase hunger,
thus promoting weight regain [27]. Therefore, a difficulty in
treating obesitymay stem from themetabolic and physiologic
responses resisting the maintenance of the decreased body
weight.
The Prevention of Obesity Using Novel Dietary Strategies
(POUNDS LOST) study funded by the National Heart, Lung,
and Blood Institute compared the effects of four different
diets (two low-fat, high carbohydrate diets and two high-fat,
low carbohydrate diets) on weight loss and further compared
the weight loss to changes in energy expenditure in 811
overweight or obese individuals over 24 months. REE mea-
surements were taken at baseline, 6 months, and 24 months.
At baseline, REE was higher for men than for women, and
there was a strong positive correlation between body weight
and REE. At 6 months, REE decreased significantly with
weight loss, and this has been proposed to be a contributing
factor in weight regain. REE increased back to baseline at
24 months, when weight regain was still less than 50% in
these patients. These findings suggest that a good portion
of weight regain occurs within the two years while REE is
decreased, but that regain continues even after REE returns
to normal. This is consistent with epidemiologic evidence
that demonstrates weight regain beyond 24 months [20]. It
is therefore unclear what role this return to baseline REE at
24 months plays in weight regain.
There is also significant evidence that the composition
of the diet used for weight loss influences REE and weight
regain.Majormacromolecule nutrients such as carbohydrate,
protein, and fat in food stimulate oxygen consumption
differently [26]. This in turn may influence changes in body
weight and possibly weight regain [26]. Several studies have
shown that high-protein, low-carbohydrate diets are effective
for short-term weight loss, but evidence remains sparse
in studying successful long-term weight loss and weight
maintenance [29–31] The POUNDS LOST study examined
the effect of diet composition on body weight and REE but
found that both were unaffected by diet composition [26].
Ebbeling et al. randomly assigned obese patients to one of
the three diets over four weeks: low fat, low glycemic index,
and very low carbohydrate [28]. Among the participants who
lost 10% to 15% baseline weight, REE decreased the least
in the very low carbohydrate group, suggesting that a low-
carbohydrate dietmay deter weight regain [28]. Furthermore,
another study compared five diets that differed in protein
content and glycemic index in order to determine the best
diet to prevent weight regain over a 26-week period [32].
Results from this study found that the high-protein, low-
glycemic index diet was best for maintenance of weight loss
[32]. Consistent with these findings, one group studying diet-
induced obese rats observed a shift from fat to carbohydrate
metabolism that occurred duringweight regain [33]. Further-
more, another diet-induced rat obesity study found that if
rats are maintained on a low carbohydrate, high fat diet and
subsequently switched to a standard chow diet, they gained
much more weight than the rats which were maintained on
the standard chow diet throughout the study [34]. Future
studies should be carried out over a longer duration in order
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to further evaluate a role for low-carbohydrate diets in the
prevention of weight regain. Energy restriction and weight
loss is believed to involve a shift in metabolism that favors
lipid oxidation over carbohydrate, with later weight regain
coinciding with a metabolic reversal back to carbohydrates
[33, 35]. Thus, a low carbohydrate diet may protect against
weight regain by blocking this metabolic reversal.
3. Neuroendocrine Adaptations Opposing
Weight Loss
Although initially promising, the discovery of the hormone
leptin and its contribution to obesity in the leptin knockout
mouse (ob/ob) did not prove to be a “quick fix” to the problem
of obesity. Despite observations in wild type and ob/ob mice
that leptin supplementation decreases feeding and weight
gain, there is little evidence to support leptin deficiency
as an etiologic factor in sporadic human obesity [36–39].
Indeed, leptin levels in humans are correlated with weight
gain and therefore increase in obesity, and evidence suggests
that resistance to leptin’s anorexigenic effects plays a role in
this phenomenon [40–44]. In addition to leptin, a multitude
of other neuroendocrine signals influence food intake and
body weight. This ever-expanding list of appetite-mediating
hormones includes leptin, ghrelin, cholecystokinin (CCK),
peptide YY (PYY), insulin, pancreatic polypeptide (PP),
glucagon-like peptide 1 (GLP-1), and uroguanylin [45–52].
These hormonal signals are integrated by the hypothalamus,
which anchors various neuroendocrine axes including the
hypothalamic-pituitary-thyroid axis and the hypothalamic-
pituitary-adrenal axis. These axes in turn contribute to body
weight homeostasis [53, 54]. Given the central role that
these pathways play in the regulation of appetite, energy
expenditure, and body weight, it is not surprising that this
neuroendocrine milieu is profoundly altered in response to
obesity and subsequent weight loss.
Recently, an important study by Sumithran et al. inves-
tigated the compensatory regulation of satiety hormones
following weight loss in obese patients [55].The investigators
enrolled 50 overweight or obese patients and subjected them
to a significant weight loss regimen over 10 weeks. Levels
of circulating satiety hormones were measured at week 10,
and then again at week 62 to assess long-term persistence
of hormonal changes. Importantly, weight loss in obese
patients resulted in significant and persistent reductions in
levels of leptin, peptide YY, cholecystokinin, and insulin and
increases in levels of ghrelin and pancreatic polypeptide. All
of these hormonal changes are believed to be permissive of
weight regain (with the exception of increased pancreatic
polypeptide) and these observations are consistent with the
increased subjective appetite reported by subjects. Indeed, the
investigators report a strong linear correlation between the
observed decreases in leptin and weight regain in patients.
In another study, Varady et al. also showed a significant
decrease in leptin levels following weight loss of over 5%,
but not below 5%, suggesting that a critical level of weight
loss is necessary to induce compensatory changes [56].These
findings are in accordance with other recent literature that
demonstrated blunted release of the satiety hormones PYY
and GLP-1 secondary to weight loss [57, 58].
In addition to altering levels of key satiety hormones,
weight loss also has been shown to be associated with changes
in several key hypothalamic-pituitary neuroendocrine axes
that may promote weight regain. The thyroid hormone axis
has long been associatedwith energy expenditure, andweight
gain is a common clinical presentation in patients with
hypothyroidism [59].The hypothalamus secretes thyrotropin
releasing hormone (TRH) which induces secretion of thy-
roid stimulating hormone (TSH) into the circulation by
the anterior pituitary [60]. This in turn causes the thyroid
gland to secrete thyroid hormones T3 and T4, which are
involved in regulation of body temperature and energy
expenditure, possibly by regulation of uncoupler proteins in
the mitochondrial apparatus [61]. Consistent with this role as
a mediator of energy expenditure, TSH has been shown to be
inversely proportional to resting energy expenditure (REE),
and feedback fromT3 and T4 drives downTSH and increases
energy expenditure [62–64]. Importantly, weight loss and
dietary energy restriction has been shown to suppress the
thyroid hormone axis in many studies [65–69]. Although
the durability of this response during the natural history of
weight regain remains unclear, this adaptive response would
reduce REE and be permissive of weight regain.
The hypothalamus also regulates body weight through
the hypothalamus-pituitary-adrenal axis, which regulates
cortisol levels in the circulation. Clinically, cortisol excess
in humans (exemplified by Cushing syndrome) is associated
with obesity [70]. This proobesity effect is at least partially
due to suppression of leptin-induced satiety [71]. Importantly,
cortisol levels increase markedly with energy restriction in
a number of human studies [72–75]. This represents yet
another mechanism by which the hypothalamus responds
to weight loss and activates pathways that promote weight
regain. These findings advance our understanding of weight
regain by highlighting the importance of alterations to the
neuroendocrinemilieu in the compensatory response follow-
ing weight loss.
4. Gastrointestinal Motility
The roles that gastric emptying and gastrointestinal motility
play in obesity and weight loss are largely unclear and the
evidence is sometimes contradictory. Some evidence suggests
that obese individuals may exhibit accelerated gastric emp-
tying, although the opposite has been shown as well [76–
80]. Increased emptying may decrease the negative feedback
induced by mechanical stretching and the presence of nutri-
ents in the stomach. This would allow the consumption of
larger and more frequent meals [81]. Consistent with this
hypothesis, patients with pathologic delayed gastric emptying
(as seen in gastroparesis and dyspepsia) exhibit dramatically
decreased feeding and early satiety [82, 83]. However, a
competing hypothesis suggests that less severe delayed gastric
emptying in obesity may actually promote feeding through
delayed delivery of nutrients to the duodenum and the asso-
ciated release of satiety hormones. Recently, new evidence has
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emerged that this latter mechanism may in fact contribute to
weight regain in obese patients [84].
Several studies have shown that weight loss induces
a delay in gastric emptying, although others report no
change [77, 84–87]. Interestingly, among the studies that
documented a difference, Verdich et al. examined the time
course of gastric emptying following weight loss. Although
overall gastric emptying was unaffected, the investigators
reported a delay in early emptying in the first 30 minutes
after a meal [84]. The authors suggest that this early delay
in the delivery of nutrients to the duodenum may delay the
release of satiety hormones from the duodenum and promote
feeding. Additional studies in gastric bypass patients provide
further evidence for the permissive role of gastric emptying
in weight regain. Increased transit time through the stomach
is one of the hallmarks of gastric bypass, and as such it makes
a good model of increased gastric emptying. Importantly,
postprandial levels of the gut-derived satiety hormones PYY
and GLP-1 are blunted in patients who lost weight through
energy restriction but are increased in gastric bypass patients
[57, 58, 88, 89]. Therefore, delayed gastric emptying seen in
energy-restrictedweight loss prolongs feeding by suppressing
satiety hormones, while gastric bypass surgery accelerates
gastric emptying and increases secretion of such hormones.
These findings suggest a permissive role of gastric emptying
in weight regain, although more studies into the exact nature
of this relationship are necessary.
5. Subjective Appetite
Appetite represents the integration of biochemical, mechan-
ical, neurological, and psychological pathways that regulate
food intake into a single output: the desire to eat. Therefore,
an increase in subjective appetite accompanies the described
physiologic changes following weight loss that promote
weight regain [35]. Indeed,multiple studies have documented
this phenomenon, and these increases in appetite are sus-
tained [55, 70]. Evidence suggests that additional changes
occur to appetite beyond a simple increase in the desire
for food. Cameron et al. showed that the perceived reward
properties of food increase following weight loss, encour-
aging greater consumption [90]. Another study compared
taste preferences between lean and formerly obese patients by
having them rate different nutrient solutions based on taste
[91]. Notably, lean subjects preferred a solution low in fat and
sugar, while the formerly obese group preferred a solution
high in both fat and sugar. Such a solution was extremely
calorie dense and obesogenic. Therefore, weight loss induced
overeating and preference for higher calorie foods. These
changes would promote weight regain and represents the
summation of all the compensatory mechanisms discussed
previously.
6. Conclusion
The evidence presented in this paper provides novel insights
into the nature of weight loss and associated compensatory
changes. Further, it suggests that multiple redundant mech-
anisms have evolved to maintain body weight and thereby
counteract a reduction in caloric intake. This redundancy
may in part explain the high degree of failure and weight
regain observed following weight loss through lifestyle inter-
vention [20]. In this context, it is noteworthy that low-dose
leptin replacement monotherapy has been shown to reverse
many of the neurologic, hormonal, and behavioral adapta-
tions that promote weight regain, despite the heterogeneous
etiologies underlying weight regain [92–94]. These findings,
coupled with the ongoing clinical development of targeted
therapies to many other satiety pathways, lay the foundation
for future strategies that combine lifestyle modification to
induce weight loss with pharmacological intervention to
prevent weight regain [95].
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